Precigen, Inc. (PGEN)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS74017N1054
4.56 USD
-2.15% today Updated 13 Nov 2026 15:24
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Precigen, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 15:24. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
24 Mar 2027
in 131 days · 17:00 · estimate 0.06
Last results
0.08 vs 0.08 estimated
04 Nov 2026 · Beat +1.5%
Beat the estimate
6 of 12
6 missed · 0 in line · 4 beats in a row
Average surprise
-44.0%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 24 Mar 2027 17:00 | 0.06 | — | — | Upcoming |
| 04 Nov 2026 16:00 | 0.08 | 0.08 | +1.5% | Beat |
| 04 Aug 2026 16:00 | -0.01 | 0.05 | +475.1% | Beat |
| 13 May 2026 16:00 | -0.04 | -0.02 | +50.0% | Beat |
| 25 Mar 2026 16:00 | -0.08 | -0.01 | +88.1% | Beat |
| 13 Nov 2025 16:00 | -0.09 | -1.06 | -1,015.8% | Miss |
| 12 Aug 2025 16:00 | -0.08 | -0.08 | +4.1% | Beat |
| 14 May 2025 16:00 | -0.08 | -0.18 | -125.0% | Miss |
| 19 Mar 2025 16:00 | -0.05 | -0.03 | +37.0% | Beat |
| 14 Nov 2024 16:00 | -0.09 | -0.09 | -3.8% | Miss |
| 14 Aug 2024 16:00 | -0.09 | -0.10 | -11.0% | Miss |
| 14 May 2024 16:00 | -0.08 | -0.10 | -17.7% | Miss |
| 19 Mar 2024 16:00 | -0.08 | -0.09 | -10.1% | Miss |
| 09 Nov 2023 17:00 | -0.08 | -0.08 | 0.0% | In line |
| 09 Aug 2023 08:00 | -0.10 | -0.08 | +22.6% | Beat |
| 10 May 2023 08:00 | -0.10 | -0.10 | 0.0% | In line |
| 06 Mar 2023 16:00 | -0.12 | -0.11 | +8.3% | Beat |
| 09 Nov 2022 16:00 | -0.09 | -0.04 | +55.6% | Beat |
| 08 Aug 2022 16:00 | -0.14 | -0.08 | +39.4% | Beat |
| 09 May 2022 16:00 | -0.13 | -0.09 | +27.7% | Beat |
| 01 Mar 2022 08:00 | -0.12 | -0.13 | -8.3% | Miss |
| 08 Nov 2021 08:00 | -0.13 | -0.15 | -11.1% | Miss |
| 09 Aug 2021 16:00 | -0.12 | -0.10 | +18.3% | Beat |
| 10 May 2021 16:00 | -0.15 | -0.11 | +29.0% | Beat |
| 01 Mar 2021 16:00 | -0.21 | -0.22 | -2.3% | Miss |
| 09 Nov 2020 08:00 | -0.14 | -0.18 | -27.2% | Miss |
| 10 Aug 2020 16:00 | -0.13 | -0.26 | -92.6% | Miss |
| 06 May 2020 17:00 | -0.24 | -0.35 | -45.8% | Miss |
| 02 Mar 2020 16:00 | -0.29 | -0.28 | +3.0% | Beat |
| 12 Nov 2019 07:00 | -0.25 | -0.35 | -37.3% | Miss |
| 08 Aug 2019 17:00 | -0.29 | -0.25 | +15.3% | Beat |
| 09 May 2019 16:00 | -0.25 | -0.40 | -60.0% | Miss |
| 28 Feb 2019 16:00 | -0.13 | -0.41 | -215.4% | Miss |
| 08 Nov 2018 16:00 | -0.23 | -0.44 | -91.3% | Miss |
| 13 Aug 2018 07:00 | -0.23 | -0.51 | -121.7% | Miss |
| 10 May 2018 16:00 | -0.24 | -0.32 | -33.7% | Miss |
| 01 Mar 2018 16:00 | -0.30 | -0.23 | +23.3% | Beat |
| 09 Nov 2017 16:00 | -0.15 | -0.35 | -131.6% | Miss |
| 09 Aug 2017 16:00 | -0.10 | -0.23 | -125.6% | Miss |
| 10 May 2017 16:00 | -0.22 | -0.25 | -12.2% | Miss |
| 01 Mar 2017 17:00 | -0.22 | -0.26 | -19.9% | Miss |
| 09 Nov 2016 16:00 | -0.17 | -0.25 | -46.9% | Miss |
| 09 Aug 2016 16:00 | -0.28 | -0.42 | -48.2% | Miss |
| 10 May 2016 16:00 | -0.16 | -0.13 | +18.8% | Beat |
| 29 Feb 2016 16:00 | -0.22 | -0.30 | -37.4% | Miss |
| 09 Nov 2015 16:00 | -0.13 | -0.08 | +41.5% | Beat |
| 10 Aug 2015 16:00 | 0.06 | 0.01 | -82.4% | Miss |
| 11 May 2015 16:00 | -0.12 | -0.26 | -106.2% | Miss |
| 02 Mar 2015 16:00 | -0.14 | 0.18 | +224.1% | Beat |
| 13 Nov 2014 16:00 | -0.16 | -0.53 | -231.3% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 9.7M | +146.7% | -250.6M | -2,588.2% | -1.37 | -191.5% | -89.8M |
| 2024 | 3.9M | -36.9% | -126.2M | -3,216.2% | -0.47 | -20.5% | -76.8M |
| 2023 | 6.2M | -76.9% | -95.9M | -1,540.6% | -0.39 | -378.6% | -68.5M |
| 2022 | 26.9M | — | 28.3M | 105.2% | 0.14 | — | -70M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 13 Nov 2026 In progress | 4.48 | 4.96 | 4.31 | 4.57 | +2.24% | 25,131,925 | |
| 02 Nov 2026 – 06 Nov 2026 | 5.36 | 5.48 | 3.92 | 4.47 | -35.59% | 76,699,300 | |
| 26 Oct 2026 – 30 Oct 2026 | 6.24 | 7.04 | 5.96 | 6.94 | +12.12% | 25,857,000 | |
| 19 Oct 2026 – 23 Oct 2026 | 6.45 | 6.95 | 6.15 | 6.19 | -3.13% | 26,882,200 | |
| 12 Oct 2026 – 16 Oct 2026 | 7.77 | 7.87 | 6.31 | 6.39 | -18.18% | 18,198,000 | |
| 05 Oct 2026 – 09 Oct 2026 | 8.51 | 8.60 | 7.35 | 7.81 | -8.55% | 26,737,700 | |
| 28 Sep 2026 – 02 Oct 2026 | 7.61 | 8.98 | 7.50 | 8.54 | +10.19% | 30,283,000 | |
| 21 Sep 2026 – 25 Sep 2026 | 7.84 | 8.27 | 7.19 | 7.75 | -0.39% | 25,307,400 | |
| 14 Sep 2026 – 18 Sep 2026 | 6.86 | 8.04 | 6.76 | 7.78 | +13.58% | 32,771,100 | |
| 08 Sep 2026 – 11 Sep 2026 | 6.89 | 7.02 | 6.54 | 6.85 | -3.52% | 10,792,000 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule (opens in a new tab) 10 Nov 2026 11:30
- What Makes Precigen (PGEN) a New Buy Stock (opens in a new tab) Zacks · 09 Nov 2026 16:00
- PGEN Q3 Earnings Call Highlights Launch Momentum and Competition (opens in a new tab) Zacks · 09 Nov 2026 14:00
- Precigen (PGEN) Stock Looks Fully Priced On Current Earnings (opens in a new tab) Simply Wall St. · 06 Nov 2026 17:20
- Precigen (PGEN) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 17:20
- Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock (opens in a new tab) Stocktwits · 05 Nov 2026 11:55
- Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12 (opens in a new tab) Benzinga · 05 Nov 2026 10:34
- Precigen Inc (PGEN) Q3 2026 Earnings Call Highlights: Triple-Digit Revenue Surge, First ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 05:18
- What Precigen (PGEN) Said on Its Q3 Earnings Call (opens in a new tab) MarketBeat · 05 Nov 2026 05:14
- Precigen, Inc. (PGEN) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 05 Nov 2026 04:54
- Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss Estimates (opens in a new tab) Zacks · 04 Nov 2026 21:50
- Can Precigen (PGEN) Justify Its Valuation As Inovio Approval Tests Papzimeos? (opens in a new tab) Simply Wall St. · 03 Nov 2026 05:11
- Precigen Gears Up to Report Q3 Earnings: What Can Investors Expect? (opens in a new tab) Zacks · 02 Nov 2026 14:42
- Precigen Sinks 26% as Inovio Wins FDA Approval for Papzimeos Rival Days Before Earnings (opens in a new tab) TIKR · 02 Nov 2026 14:36
- PGEN Stock Crashes Premarket: Retail Sees Buyout Opening As Inovio Rival Crashes The Party Before Earnings (opens in a new tab) Stocktwits · 02 Nov 2026 08:40
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 4.66 USD
- Market cap
- 1.7B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 0.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 6.7 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 1.8 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -27.6× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 42.36× | Weak | 30.56× |
| P/E (forward) | -21.18× | Weak | 14.16× |
| Price / book | 19.91× | Weak | 3.5× |
| Price / sales | 10.65× | Weak | 3.33× |
| EV / EBITDA | 45.82× | Weak | 11.19× |
| Free cash flow yield | -5.2% | Weak | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 74.5% | Good | 54.9% |
| Operating margin | 21.4% | Good | 5.8% |
| Net margin | 15.6% | Good | 1.2% |
| Return on equity | 38.8% | Good | 4.4% |
| Return on assets | 11% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | -28.9% | Weak | 10.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 1.18× | Fair | 0.4× |
| Net debt / EBITDA | 1.38× | Good | 1.46× |
| Interest cover | -27.57× | Weak | 2.17× |
| Current ratio | 5.58× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow PGEN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.